![HIIF-D [R10C101-250nM]](/static/images/cells-no_picture.jpg)
-
平臺(tái)編號(hào)：bio-68427
-
國(guó)際編號(hào)：CRL-8200?
-
細(xì)胞信息： HIIF-D [R10C101-250nM]
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
HIIF-D [R10C101-250nM]
運(yùn)輸方式：凍存運(yùn)輸
數(shù)量：大量
ATCC Number：CRL-8200?
生長(zhǎng)狀態(tài)：貼壁生長(zhǎng)
器官來源：卵巢
是否是腫瘤細(xì)胞：0
物種來源：倉(cāng)鼠
規(guī)格：48T Designations: HIIF-D [R10C101-250nM]
Depositors: ?Biogen, Inc., Biogen N.V.
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Cricetulus griseus
Morphology:
Source: Organ: ovary
Cellular Products:human interferon gamma
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Applications:in another host, produces protein interferon gamma
Gender: female
Comments:This clone was selected after growth in 250 nM methotrexate. [40107 ]
The HIIF-D line was established from CHO DHFR- cells (deficient in dihydrofolate reductase) co-transformed with pSV-IFN-gamma (containing the coding sequence for human interferon gamma) and pAdD26SV(A)-3 (containing the mouse DHFR coding sequences).
The cells produce human gamma interferon.
Constructed by replacing the HindIII/BglII fragment containing murine Dfhr with the IFNG sequence. [40107 ]
The pBR322-derived sequences were also modified by replacing a EcoRI/PvuII fragment that inhibits replication in mammalian cells with an EcoRI/SalI fragment from pML. [40107 ]
Also contains pAdD26SV(A)-3 which was cotransformed to express murine Dhfr. Both plasmids were digested with EcoRI before transformation. [40107 ]
The order of the major features in this plasmid is: SalI - SV40 promoter - HindIII - IFNG - SV40t - SV40 polyadenylation - EcoRI - ampR - ori. [40107 ]
Propagation: ATCC complete growth medium: Alpha minimum essential medium without nucleosides and with 250 nM methotrexate; 90%; fetal bovine serum, 10%
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing: Protocol: Remove medium, add fresh trypsin (0.25%) and let the culture sit for several minutes. Remove the trypsin and incubate the cells at 37C until they begin to detach. Add fresh medium, asperate and dispense into new flasks.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended
Medium Renewal: 2 to 3 times per week
Preservation: Freeze medium: complete growth medium, 95%; DMSO, 5%
References: 40107: Fiers WC, Allet B. DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields. US Patent 5,004,689 dated Apr 2 1991
數(shù)量：大量
ATCC Number：CRL-8200?
生長(zhǎng)狀態(tài)：貼壁生長(zhǎng)
器官來源：卵巢
是否是腫瘤細(xì)胞：0
物種來源：倉(cāng)鼠
規(guī)格：48T Designations: HIIF-D [R10C101-250nM]
Depositors: ?Biogen, Inc., Biogen N.V.
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Cricetulus griseus
Morphology:
Source: Organ: ovary
Cellular Products:human interferon gamma
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Applications:in another host, produces protein interferon gamma
Gender: female
Comments:This clone was selected after growth in 250 nM methotrexate. [40107 ]
The HIIF-D line was established from CHO DHFR- cells (deficient in dihydrofolate reductase) co-transformed with pSV-IFN-gamma (containing the coding sequence for human interferon gamma) and pAdD26SV(A)-3 (containing the mouse DHFR coding sequences).
The cells produce human gamma interferon.
Constructed by replacing the HindIII/BglII fragment containing murine Dfhr with the IFNG sequence. [40107 ]
The pBR322-derived sequences were also modified by replacing a EcoRI/PvuII fragment that inhibits replication in mammalian cells with an EcoRI/SalI fragment from pML. [40107 ]
Also contains pAdD26SV(A)-3 which was cotransformed to express murine Dhfr. Both plasmids were digested with EcoRI before transformation. [40107 ]
The order of the major features in this plasmid is: SalI - SV40 promoter - HindIII - IFNG - SV40t - SV40 polyadenylation - EcoRI - ampR - ori. [40107 ]
Propagation: ATCC complete growth medium: Alpha minimum essential medium without nucleosides and with 250 nM methotrexate; 90%; fetal bovine serum, 10%
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing: Protocol: Remove medium, add fresh trypsin (0.25%) and let the culture sit for several minutes. Remove the trypsin and incubate the cells at 37C until they begin to detach. Add fresh medium, asperate and dispense into new flasks.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended
Medium Renewal: 2 to 3 times per week
Preservation: Freeze medium: complete growth medium, 95%; DMSO, 5%
References: 40107: Fiers WC, Allet B. DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields. US Patent 5,004,689 dated Apr 2 1991
